- Home
- ABL vs MLTX Comparison
ABL vs MLTX Comparison
Compare ABL & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- MLTX
- Stock Information
- Founded
- ABL 2004
- MLTX 2021
- Country
- ABL United States
- MLTX Switzerland
- Employees
- ABL N/A
- MLTX N/A
- Industry
- ABL Investment Managers
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- MLTX Health Care
- Exchange
- ABL Nasdaq
- MLTX Nasdaq
- Market Cap
- ABL 639.8M
- MLTX 535.3M
- IPO Year
- ABL N/A
- MLTX N/A
- Fundamental
- Price
- ABL $5.97
- MLTX $9.10
- Analyst Decision
- ABL Strong Buy
- MLTX Buy
- Analyst Count
- ABL 3
- MLTX 9
- Target Price
- ABL $12.83
- MLTX $37.63
- AVG Volume (30 Days)
- ABL 971.0K
- MLTX 10.0M
- Earning Date
- ABL 11-06-2025
- MLTX 11-06-2025
- Dividend Yield
- ABL N/A
- MLTX N/A
- EPS Growth
- ABL N/A
- MLTX N/A
- EPS
- ABL N/A
- MLTX N/A
- Revenue
- ABL $161,724,466.00
- MLTX N/A
- Revenue This Year
- ABL $79.57
- MLTX N/A
- Revenue Next Year
- ABL $21.05
- MLTX N/A
- P/E Ratio
- ABL N/A
- MLTX N/A
- Revenue Growth
- ABL 69.56
- MLTX N/A
- 52 Week Low
- ABL $4.60
- MLTX $5.95
- 52 Week High
- ABL $10.30
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- ABL 40.82
- MLTX 23.15
- Support Level
- ABL $5.64
- MLTX $8.18
- Resistance Level
- ABL $6.39
- MLTX $9.54
- Average True Range (ATR)
- ABL 0.28
- MLTX 2.00
- MACD
- ABL -0.03
- MLTX -3.65
- Stochastic Oscillator
- ABL 27.74
- MLTX 5.47
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.